Tilray Plummets With $1.27B Q4 Net Loss Due To 2021 Aphria Merger

Tilray Brands (TSX: TLRY) reported a staggering Q4 2025 net loss of $1.27 billion, a massive decline compared to Q4 2024’s loss of just $15.4 million. Earnings per share also dramatically fell to a loss of $1.30, missing analyst estimates of just a $0.03 loss per share, an overwhelming 4,233% miss.

Following the news, Tilray shares fell nearly 15% in pre-market trading on the NASDAQ.

The cannabis firm’s revenue was $224.5 million for the quarter, slightly below the anticipated $233.29 million and marking a 2% decline YoY from $229.9 million. The revenue miss was primarily driven by setbacks in the cannabis and beverage segments. Cannabis revenue decreased to $67.8 million from $71.9 million last year, impacted by temporary halts in certain product lines and delays in international medical cannabis permits. Beverage revenue fell notably to $65.6 million from $76.7 million YoY, attributed to restructuring initiatives under “Project 420” and rationalization of product lines.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Gross profit shrank to $67.6 million, down from $82.4 million in the previous year, while overall gross margin contracted from 36% to 30%.

The immense quarterly loss primarily stems from a $1.4 billion non-cash impairment charge on goodwill and intangible assets dating back to the 2021 Aphria and Tilray merger, “at which time stock prices and market values for cannabis companies reflected expectations for US cannabis legalization.”

Adjusted net income plunged by 43% to $20.2 million from $35.1 million last year, translating into adjusted earnings of $0.02 per share compared to $0.04 last year. Adjusted EBITDA also declined 6% to $27.6 million from $29.5 million a year ago.

On a full-year basis, fiscal 2025 net revenue increased modestly by 4% to $821.3 million from $788.9 million in 2024. This falls below the low-end of the previously announced guidance of $850 million–$900 million. The annual net loss ballooned dramatically to $2.18 billion compared to $222.4 million in the prior year, while annual EPS also worsened significantly to a loss of $2.46 per share from $0.33 loss per share.

Cash flows from operations deteriorated further, with Tilray burning through $94.6 million compared to just $30.9 million in the previous fiscal year. Free cash flow also came at a negative $13.1 million this quarter compared to a positive $28.3 million a year ago. For the whole year, free cash flow declined to negative $120.7 million from 2024’s $51.6 million.

The company retains liquidity of $256 million, consisting of $222 million cash and $35 million in marketable securities.

For fiscal year 2026, Tilray expects adjusted EBITDA to grow between 13% to 31%, reaching $62 to $72 million, indicating cautious optimism for operational improvements.

Tilray last traded at $0.95 on the TSX.


Information for this story was found via the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Gold & Copper Stocks Everyone Keeps Asking About | Oct. 12-16 – Weekly Mining Mailbag

Similar Gold Mines Are Valued 10X Higher. Why Not This One? | JW Dumont – Granada Gold Mine

The US Interest Bill Gold Can’t Ignore | Peter Grandich

Recommended

Sage Potash Expands Sage Plain Resource to 771.5 Million Tonnes, Adds First Measured and Indicated Tonnage

Cambria’s Silver Coin Infill Program Delivers 98.56 g/t Gold Over 8.2 Metres

Related News

TIlray: Canaccord Resumes Coverage Following Aphria Transaction

Earlier this week, Tilray (NASDAQ: TLRY) finalized their merger with Aphria (NASDAQ: APHA) (TSX: APHA),...

Saturday, May 8, 2021, 04:20:00 PM

Tilray Quietly Announces US$400 Million At-The-Market Financing

Tilray Brands (TSX: TLRY) this morning attempted to quietly announce that it will be conducting...

Thursday, March 3, 2022, 08:19:02 AM

Tilray Selected To Supply Medical Cannabis For French Experimental Program

Tilray Inc (NASDAQ: TLRY) has expanded its international operations to now include France. The company...

Tuesday, January 26, 2021, 07:55:19 AM

Tilray: Canaccord Lowers Target On Expected Adult-Use Sales Slump, Revised Hexo Deal

Earlier this week, Tilray Brands (TSX: TLRY) announced an update to their strategic alliance with...

Friday, June 17, 2022, 10:49:29 AM

Tilray Q3 FY2025 Results: Shares Slump On 656% Wider Net Loss

Tilray Brands (TSX: TLRY) has reported its financial results for Q3 of fiscal 2025, ending...

Thursday, April 10, 2025, 07:21:00 AM